Latest Breaking News On - Enliven therapeutics - Page 1 : vimarsana.com

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 1,133 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 1,133 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $20.06, for a total transaction of $22,727.98. The transaction was disclosed in a legal filing with the SEC, which […]

Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total value of $278,160.00. The transaction was disclosed in a filing with the SEC, which is available at […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 4,250 Shares

Enliven Therapeutics (NASDAQ:ELVN) Trading 6.1% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rishi Gupta Sells 1,033,300 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Rishi Gupta sold 1,033,300 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $22.14, for a total transaction of $22,877,262.00. Following the sale, the director now owns 254,814 shares of the company’s […]

Lifesci Capital Comments on Enliven Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ELVN)

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Lifesci Capital issued their Q2 2024 EPS estimates for Enliven Therapeutics in a report released on Wednesday, May 15th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Enliven Therapeutics’ current full-year earnings […]

Boulder's Enliven has cash runway into late 2026 – Boulder Daily Camera

Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.

ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024

Enliven has cash runway into late 2026 – BizWest